Seminars in Radiation Oncology
Volume 18, Issue 4 , Pages 229-233 , October 2008

Some Cases of Severe Normal Tissue Toxicity Can Be Anticipated With Ablated Fractionated Radiation With Appropriate Long-term Follow-up

  • Christopher Dolinsky, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Christopher Dolinsky, MD, Department of Radiation Oncology, Hospital of the University of Pennsylvania, 2 Donner, 3400 Spruce Street, Philadelphia, PA 19104
    • ,
  • Eli Glatstein, MD

References 

  1. Regaud C. Influence de la durée d'irradiation sur les effets déterminés dans le testicule par le Radium. C R Soc Biol. 1922;86:787–790
  2. Thames HD, Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys. 1982;8:219–226
  3. Steel GG. Basic Clinical Radiobiology. (ed 3). New York: Arnold; 2002;
  4. Abratt RP, Bogart JA, Hunter A. Hypofractionated irradiation for non-small cell lung cancer. Lung Cancer. 2002;36:225–233
  5. Withers HR. The 4 R's of radiotherapy. Adv Radiat Biol. 1975;5:241–271
  6. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. (ed 6). Philadelphia: Lippincott Williams & Wilkins; 2006;
  7. Fowler JF. An arguing point?. ESTRO. 2007;64:15
  8. Kaplan HS. On the relative importance of hypoxic cells for the radiotherapy of human tumours. Eur J Cancer. 1974;10:275–280
  9. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951;102:316–319
  10. Flickinger JC, Kondziolka D, Lunsford LD, et al. Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients (Arteriovenous Malformation Radiosurgery Study Group). Int J Radiat Oncol Biol Phys. 2000;46:1143–1148
  11. Hopewell JW, Millar WT, Ang KK. Toward improving the therapeutic ratio in stereotactic radiosurgery: Selective modulation of the radiation responses of both normal tissues and tumor. J Neurosurg. 2007;107:84–93
  12. Karlsson B, Lax I, Soderman M. Factors influencing the risk for complications following Gamma Knife radiosurgery of cerebral arteriovenous malformations. Radiother Oncol. 1997;43:275–280
  13. Chin LS, Ma L, DiBiase S. Radiation necrosis following gamma knife surgery: A case-controlled comparison of treatment parameters and long-term clinical follow up. J Neurosurg. 2001;94:899–904
  14. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  15. Roach M, Gandara DR, Yuo HS, et al. Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. J Clin Oncol. 1995;13:2606–2612
  16. Potters L, Steinberg M, Rose C, et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004;60:1026–1032
  17. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–670
  18. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63:1427–1431
  19. Beitler JJ, Badine EA, El-Sayah D, et al. Stereotactic body radiation therapy for nonmetastatic lung cancer: An analysis of 75 patients treated over 5 years. Int J Radiat Oncol Biol Phys. 2006;65:100–106
  20. Gerard A, Buyse M, Nordlinger B, et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer (Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC)). Ann Surg. 1988;208:606–614
  21. Goldberg PA, Nicholls RJ, Porter NH, et al. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: Reduction in local treatment failure. Eur J Cancer. 1994;30A:1602–1606
  22. Improved survival with preoperative radiotherapy in resectable rectal cancer (Swedish Rectal Cancer Trial). N Engl J Med. 1997;336:980–987
  23. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–646
  24. Birgisson H, Pahlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: Long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23:8697–8705
  25. Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol. 2001;40:712–717
  26. Valdagni R, Italia C, Montanaro P, et al. Is the alpha-beta ratio of prostate cancer really low? (A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy). Radiother Oncol. 2005;75:74–82
  27. Fowler JF, Nahum AE, Orton CG. Point/counterpoint (The best radiotherapy for the treatment of prostate cancer involves hypofractionation). Med Phys. 2006;33:3081–3084
  28. Byhardt RW, Greenberg M, Cox JD. Local control of squamous carcinoma of oral cavity and oropharynx with 3 vs 5 treatment fractions per week. Int J Radiat Oncol Biol Phys. 1977;2:415–420
  29. Sauer R, Sautter-Bihl ML, Budach W, et al. Accelerated partial breast irradiation: Consensus statement of 3 German Oncology societies. Cancer. 2007;110:1187–1194
  30. Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;48:745–750
  31. Livsey JE, Cowan RA, Wylie JP, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57:1254–1259
  32. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63:1463–1468
  33. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol. 2005;76:1–3
  34. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66:1072–1083

PII: S1053-4296(08)00032-5

doi: 10.1016/j.semradonc.2008.04.003

Seminars in Radiation Oncology
Volume 18, Issue 4 , Pages 229-233 , October 2008

Article Tools